Clinical Trials
8 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00503451 2020-12-19
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01032148 2017-01-12
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
Phase 1 Terminated
NCT01321346 2015-11-24
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT00967044 2015-02-26
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01090973 2013-12-16
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00962507 2013-02-15
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed